Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CD73

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: CD73. Displaying page 1 of 1.
    EudraCT Number: 2016-000603-91 Sponsor Protocol Number: CA013-004 Start Date*: 2016-08-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid Tumors
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002805-36 Sponsor Protocol Number: ENGOT-OV30/NSGO Start Date*: 2017-10-23
    Sponsor Name:NSGO
    Full Title: NSGO-OV-UMB1; ENGOT-OV30: A phase II umbrella trial in patients with relapsed ovarian cancer.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) FI (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-000189-12 Sponsor Protocol Number: ABR43234 Start Date*: 2013-03-14
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular formation of adenosine
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001028-21 Sponsor Protocol Number: D6070C00005 Start Date*: 2018-09-19
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pa...
    Medical condition: Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-000899-25 Sponsor Protocol Number: FP1CLI006 Start Date*: 2016-12-16
    Sponsor Name:Faron Pharmaceuticals Ltd
    Full Title: A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail...
    Medical condition: Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10028154 Multi-organ failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000140-13 Sponsor Protocol Number: FPCLI001 Start Date*: 2008-05-09
    Sponsor Name:Faron Pharmaceuticals Limited
    Full Title: A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acut...
    Medical condition: Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001691-41 Sponsor Protocol Number: EMN29 Start Date*: 2021-12-28
    Sponsor Name:European Myeloma Network
    Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003218-42 Sponsor Protocol Number: RC18_0287 Start Date*: 2019-01-16
    Sponsor Name:CHU de Nantes
    Full Title: Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiologi...
    Medical condition: Locally advanced or metastatic Non-small-cell lung carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004651-23 Sponsor Protocol Number: IJB-SYNERGY-012017 Start Date*: 2018-10-16
    Sponsor Name:Institut Jules Bordet
    Full Title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative ...
    Medical condition: Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003890-91 Sponsor Protocol Number: BIOOPA Start Date*: 2020-09-29
    Sponsor Name:Medical University of Warsaw
    Full Title: The development of innovative advanced therapy medicinal product (biological dressing of the human race) in the treatment of Epidermolysis Bullosa (EB) and other chronic wounds.
    Medical condition: BIOOPA dressing will be used in the treatment of wounds in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal injury (second degree burn).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005260-15 Sponsor Protocol Number: FPCLI002 Start Date*: 2016-02-10
    Sponsor Name:Faron Pharmaceuticals Ltd
    Full Title: A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera...
    Medical condition: Adult patients diagnosed with moderate or severe Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003083 ARDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002736-33 Sponsor Protocol Number: ET16-073 Start Date*: 2017-04-27
    Sponsor Name:CENTRE LEON BERARD
    Full Title: CHEMOIMMUNE - A Phase II study evaluating an anti-PD1 monoclonal antibody (pembrolizumab) in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 03:33:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA